Overview

Pioglitazone in Thyroid Cancers

Status:
Completed

Trial end date:
2017-03-31

Target enrollment:

Participant gender:

Summary

Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan

Collaborator:

National Cancer Institute (NCI)

Treatments:

Pioglitazone